SecBot SecBot
Biotech Drug Report Generated Nov 4, 2026

Mektovi

PFE·PFIZER INC
NEUTRAL
Drug Impact Rating4/10
Trial phase
Approved
Time to market
Already on the market. First FDA approval was June 27, 2018 for melanoma; NSCLC label expansion approved October 11, 2023.
Why 4/10
Mektovi is already FDA-approved and commercially marketed with no pending PDUFA date or pivotal readout in the next 12 months. As an approved product at a large diversified pharma, it lacks a hard binary catalyst, capping the impactScore at 4 per the rubric.
Actionable Insight NEUTRAL

Mektovi has no pending PDUFA date or pivotal readout; the next meaningful event would be any future label expansion data (e.g., the ongoing Phase 2 pediatric craniopharyngioma trial), but that is years from a decision. For Pfizer investors, Mektovi is a steady-growth contributor within a diversified oncology portfolio; the more immediate binary catalysts for PFE stock are elsewhere (e.g., Elrexfio, pipeline readouts).

Price Chart

Loading chart...

Executive Summary

Mektovi (binimetinib) is an FDA-approved oral MEK inhibitor developed by Pfizer (NYSE: PFE) through its acquisition of Array BioPharma. It is used exclusively in combination with Braftovi (encorafenib) to treat BRAF V600-mutant melanoma (approved 2018) and BRAF V600E-mutant metastatic non-small cell lung cancer (approved 2023). The combined Braftovi/Mektovi franchise generated $716 million in 2025 revenue (up 18% YoY) and continues to grow, with recent label approvals in the UK and Singapore. However, Mektovi has no pending PDUFA date or pivotal readout, and generic competition is emerging (Alembic received tentative FDA approval with 180-day exclusivity). For Pfizer, a $62+ billion diversified pharma, Mektovi is a steady but non-binary contributor within a broader oncology portfolio.

How It Works

Mektovi (binimetinib) is a targeted cancer pill that blocks MEK1 and MEK2, two proteins in the MAPK signaling pathway that cancer cells use to grow and divide. It is always given together with a BRAF inhibitor called Braftovi (encorafenib), which blocks a different part of the same pathway. This two-pronged attack is designed to more effectively shut down cancer growth in tumors that have a BRAF V600 mutation.

Trial Status

Mektovi is FDA-approved and commercially marketed in the U.S. for two indications: (1) BRAF V600E/K mutant unresectable or metastatic melanoma (COLUMBUS Phase 3 trial), and (2) BRAF V600E mutant metastatic NSCLC (PHAROS Phase 2 trial). It is also approved in the EU, UK, Singapore, and other markets. Ongoing trials include a Phase 2 study in pediatric adamantinomatous craniopharyngioma (NCT05286788) and various investigator-sponsored combination studies, but no new pivotal readouts are imminent.

The Two-Sided Case

▲ Bull Case4
Braftovi/Mektovi combined revenue grew 18% year-over-year to $716 million in 2025, and Q2 2026 revenue was $174 million (up 28% YoY), showing strong commercial momentum driven by the NSCLC label expansion.
The drug is approved in both the U.S. and EU for melanoma and NSCLC, with recent additional approvals in the UK (NICE, May 2026) and Singapore (November 2026), expanding the addressable market.
Pfizer's large commercial infrastructure and oncology salesforce support continued market penetration; Jefferies analysts estimated the regimen could capture 15-20% of the BRAF-mutant NSCLC market, translating to $250-300 million in annual U.S. sales by 2027.
Mektovi is a well-established targeted therapy with a clean safety profile and is part of Pfizer's broader oncology portfolio, which is a strategic growth priority for the company.
▼ Bear Case4
Generic competition is emerging: Alembic Pharmaceuticals received tentative FDA approval for binimetinib with 180-day marketing exclusivity, and the estimated U.S. market size is $259 million (12 months ending March 2026). Coripharma and Adalvo are also advancing generic versions.
Mektovi is always used in combination with Braftovi (encorafenib), so its revenue is tied to the combined brand's market share in BRAF-mutant cancers, a competitive field that includes Novartis' Tafinlar + Mekinist.
At roughly $700-800 million in combined Braftovi/Mektovi annual revenue, the product is a small part of Pfizer's $62+ billion total revenue, limiting its individual impact on the stock.
The BREAKWATER trial and February 2026 FDA approval for first-line BRAF V600E-mutant metastatic colorectal cancer used Braftovi + cetuximab + chemotherapy, NOT Mektovi, so Mektovi did not benefit from that label expansion.

Upcoming Catalysts

  • No near-term PDUFA dates or pivotal readouts specifically for Mektovi. The next potential catalyst would be data from the ongoing Phase 2 pediatric craniopharyngioma trial or any future label-expansion filing, but neither is dated.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

PFIZER INC 8-K PFE ·Originating report

Sources · 12

Hover a chip for the title
1 en.wikipedia.org2 pfizer.com3 fda.gov4 scanx.trade5 ainvest.com6 investors.pfizer.com7 drugs.com8 pfizermedical.com9 s206.q4cdn.com10 manilatimes.net11 medicalupdateonline.com12 cdn.pfizer.com